Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through video calls and online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Albores-Saavedra J, Batich K, Chable-Montero F, et al. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: A population based study. J Cutan Pathol. 2010;37:20-27.
American Joint Committee on Cancer. Merkel Cell Carcinoma. In: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010:315-323.
Christensen SR, Leffell DJ. Chapter 92: Cancer of the Skin. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2015.
Ely H, Pascucci A. Merkel cell carcinoma: Treatment with bleomycin. Dermatol Online J. 2008;14:3.
Fitzgerald TL, Dennis S, Kachare SD, et al. Dramatic increase in the incidence and mortality from Merkel cell carcinoma in the United States. Am Surg. 2015;81:802-806.
Gupta SG, Wang LC, Penas PF, et al. Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: The Dana-Farber experience and meta-analysis of the literature. Arch Dermatol. 2006;142:685-690.
Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory
metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374-1385.
Lemos BD, Storer BE, Iyer JG, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010;63:751-761.
Miller NJ, Bhatia S, Parvathaneni U, Iyer JG, Nghiem P. Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma. Curr Treat Options Oncol. 2013;14:249-263.
National Cancer Institute. Physician Data Query (PDQ). Merkel Cell Carcinoma Treatment. 2015. Accessed at www.cancer.gov/types/skin/hp/merkel-cell-treatment-pdq on April 7, 2016.
National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Merkel Cell Carcinoma. Version 1.2016. Accessed at www.nccn.org/professionals/physician_gls/pdf/mcc.pdf on April 7, 2016.
Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 Blockade with pembrolizumab in advanced
Merkel-cell carcinoma. N Engl J Med. 2016;374:2542-2552.
Paulson KG, Iyer JG, Blom A, et al. Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage. J Invest Dermatol. 2013;133:642-646.
Rodig SJ, Cheng J, Wardzala J, et al. Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. J Clin Invest. 2012;122:4645-4653.
Rollison DE, Giuliano AR, Becker JC. New virus associated with Merkel cell carcinoma development. J Natl Compr Canc Netw. 2010;8:874-880.
Wood GS, Xu YG, Aylward JL, et al. Chapter 70: Nonmelanoma skin cancers: Basal cell and squamous cell carcinomas. In: Niederhuber JE, Armitage JO, Dorshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, Pa. Elsevier: 2014.
Young JL, Ward KC, Ries LAG. Cancers of rare sites. In: Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J, eds. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD, 2007.
Donate now so we can continue to provide access to critical cancer information, resources, and support to improve lives of people with cancer and their families.